Holdings
ALPS Medical Breakthroughs ETF
As of May 31, 2026, ALPS Medical Breakthroughs ETF reported 79 positions worth US$157M. Largest: Alkermes Plc, Kymera Therapeutics, Inc. and Celcuity Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Alkermes Plc | 172K | US$7.24M | +24,555 | May 31, 2026 |
| Kymera Therapeutics, Inc. | 84,154 | US$6.85M | +13,789 | May 31, 2026 |
| Celcuity Inc. | 47,693 | US$6.34M | +6,452 | May 31, 2026 |
| Mirum Pharmaceuticals, Inc. | 62,199 | US$6.31M | +16,395 | May 31, 2026 |
| Spyre Therapeutics, Inc. | 80,958 | US$5.95M | +11,801 | May 31, 2026 |
| Cg Oncology, Inc. | 87,032 | US$5.42M | +15,135 | May 31, 2026 |
| Apogee Therapeutics, Inc. | 57,722 | US$4.74M | +8,850 | May 31, 2026 |
| Xenon Pharmaceuticals Inc. | 85,746 | US$4.69M | +16,873 | May 31, 2026 |
| Travere Therapeutics, Inc. | 95,051 | US$4.48M | +15,307 | May 31, 2026 |
| Dianthus Therapeutics, Inc. | 45,839 | US$4.26M | +7,625 | May 31, 2026 |